tiprankstipranks
Newamsterdam Pharma Company N.V. (NAMS)
NASDAQ:NAMS
US Market
NAMS
NewAmsterdam Pharma Company
RESEARCH TOOLSreports
Want to see NAMS full AI Analyst Report?

NewAmsterdam Pharma Company (NAMS) Income Statement

251 Followers

NewAmsterdam Pharma Company Income Statement

Last quarter (Q1 2026), NewAmsterdam Pharma Company's total revenue was $3.04M, an increase of 2.08% from the same quarter last year. In Q1, NewAmsterdam Pharma Company's net income was $-48.44M. See NewAmsterdam Pharma Company’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Mar 23Dec 21
Total Revenue
$ 22.50M$ 45.56M$ 14.09M$ 102.69M$ 0.00
Gross Profit
$ 22.44M$ 45.56M$ 14.09M$ 102.69M$ 0.00
Operating Expenses
$ 248.13M$ 221.85M$ 197.06M$ 106.25M$ 34.98M
Depreciation and Amortization
$ 220.00K$ 113.00K$ 49.00K$ 9.00K$ 5.00K
EBITDA
$ -242.32M$ -241.49M$ -176.86M$ -22.34M$ -41.37M
Operating Income
$ -225.68M$ -176.29M$ -182.97M$ -3.56M$ -34.98M
Other Income/Expenses
$ 21.86M$ -65.31M$ 6.06M$ -19.08M$ -6.81M
Pretax Income
$ -203.82M$ -241.60M$ -176.91M$ -22.63M$ -41.78M
Net Income
$ -203.82M$ -241.60M$ -176.94M$ -22.63M$ -41.78M
Per Share Metrics
Basic EPS
$ -1.75$ -2.56$ -2.15$ -1.19$ -3.34
Diluted EPS
$ -1.75$ -2.56$ -2.15$ -1.19$ -3.34
Weighted Average Shares Outstanding
 114.40M 94.36M 82.16M 18.97M 17.75M
Weighted Average Shares Outstanding (Diluted)
 114.40M 94.36M 82.16M 18.97M 17.75M
Currency in USD

NewAmsterdam Pharma Company Earnings and Revenue History